News | March 20, 2025
Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Overall investment in the US facility is estimated around US$50 million
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
The biosimilar Ustekinumab has been developed and manufactured by the company
Subscribe To Our Newsletter & Stay Updated
